^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    AstraZeneca Press Release
    Title:

    LYNPARZA (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer

    Published date:
    01/19/2018
    Excerpt:
    AstraZeneca and Merck & Co., Inc...has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    12/16/2014
    Excerpt:
    Lynparza is indicated as monotherapy for the...maintenance treatment of adult patients with platinum‑sensitive relapsed high‑grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum‑based chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:...for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC) /Fallopian Tube/Primary Peritoneal Cancer...Recurrence Therapy for Platinum-Sensitive Disease...Preferred Regimens…targeted Therapy (single agents)...Olaparib